Article
Oncology
Angela Damato, Francesca Bergamo, Lorenzo Antonuzzo, Guglielmo Nasti, Francesco Iachetta, Alessandra Romagnani, Erika Gervasi, Mario Larocca, Carmine Pinto
Summary: The NIVACOR trial demonstrated that the combination of nivolumab with FOLFOXIRI/bevacizumab in treating metastatic colorectal cancer patients with RAS/BRAF mutations was well tolerated with manageable adverse events, although some patients experienced mild to moderate toxicity, particularly related to FOLFOXIRI/bevacizumab.
FRONTIERS IN ONCOLOGY
(2021)
Editorial Material
Oncology
Irene S. Yu, Jonathan M. Loree
Summary: This study evaluated the clinical conundrum of triplet versus doublet chemotherapy in combination with targeted therapy for metastatic left-sided RAS/BRAF wild-type colorectal cancer, providing important evidence comparing the efficacy of FOLFOXIRI plus bevacizumab and FOLFOX plus panitumumab in this population.
Article
Gastroenterology & Hepatology
Keisuke Kazama, Manabu Shiozawa, Masakatsu Numata, Nobuhiro Sugano, Sumito Sato, Mamoru Uchiyama, Maho Sato, Toru Aoyama, Hiroshi Tamagawa, Takashi Oshima, Norio Yukawa, Yasushi Rino
Summary: In a retrospective cohort study conducted at a cancer center in Japan, it was found that the modified FOLFOXIRI + BV regimen (group M) showed more favorable efficacy and safety in metastatic colorectal cancer patients, potentially serving as a better fit for Asian patients and an alternative upfront chemotherapy option for mCRC.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
(2022)
Article
Oncology
Hong Zhou, Yuehui Wang, Yanfang Lin, Wenjie Cai, Xiaofeng Li, Xiaomeng He
Summary: This study investigated the efficacy and safety of camrelizumab when added to XELOX chemotherapy plus bevacizumab or regorafenib as first-line therapy for mCRC. Results showed that this combination therapy was feasible and produced a high response rate of 72% in Chinese patients with MSS mCRC, with generally tolerable and manageable toxicities.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Carlotta Antoniotti, Marco M. Germani, Daniele Rossini, Sara Lonardi, Filippo Pietrantonio, Daniele Santini, Federica Marmorino, Giacomo Allegrini, Francesca Daniel, Alessandra Raimondi, Beatrice Borelli, Alberto Zaniboni, Veronica Conca, Jim Abraham, David Spetzler, Evaristo Maiello, Alessandra Boccaccino, Alessandro Passardi, Mirella Giordano, Emiliano Tamburini, Michael W. Korn, Gianluca Masi, Chiara Cremolini
Summary: This study aimed to evaluate the efficacy and safety of upfront chemotherapy intensification in early-onset metastatic colorectal cancer patients (<50 years old) with FOLFOXIRI/bev treatment, as well as explore their tumor genomic profiling. Results showed lower risk of adverse events in patients aged <50 years during treatment, and FOLFOXIRI/bev demonstrated a better efficacy/safety balance in this age group.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Carlotta Antoniotti, Daniele Rossini, Filippo Pietrantonio, Aurelie Catteau, Lisa Salvatore, Sara Lonardi, Isabelle Boquet, Stefano Tamberi, Federica Marmorino, Roberto Moretto, Margherita Ambrosini, Emiliano Tamburini, Giampaolo Tortora, Alessandro Passardi, Francesca Bergamo, Alboukadel Kassambara, Thomas Sbarrato, Federica Morano, Giuliana Ritorto, Beatrice Borelli, Alessandra Boccaccino, Veronica Conca, Mirella Giordano, Clara Ugolini, Jacques Fieschi, Alexia Papadopulos, Clementine Massoue, Giuseppe Aprile, Lorenzo Antonuzzo, Fabio Gelsomino, Erika Martinelli, Nicoletta Pella, Gianluca Masi, Gabriella Fontanini, Luca Boni, Jerome Galon, Chiara Cremolini
Summary: The addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab is safe and improves progression-free survival in previously untreated metastatic colorectal cancer patients.
Article
Medicine, General & Internal
Sietske C. van Nassau, Marinde J. Bond, Ilva Scheerman, Jesper van Breeschoten, Rob Kessels, Liselot B. Valkenburg-van Iersel, Henk M. Verheul, Tineke E. Buffart, Leonie J. Mekenkamp, Valery E. Lemmens, Miriam Koopman, Guus M. Bol
Summary: The prescription rates of FOLFOXIRI-B have marginally increased in the last 5 years in the Netherlands, but still below expectations. Most medical oncologists discuss this treatment option, mainly due to lower awareness of guidelines and trial results, with toxic effects being the most reported reason to prefer alternative regimens.
Article
Oncology
Y. Sunakawa, H. Satake, J. Usher, Y. Jaimes, Y. Miyamoto, M. Nakamura, M. Kataoka, M. Shiozawa, A. Takagane, T. Terazawa, T. Watanabe, K. Ishiguro, C. Tanaka, M. Takeuchi, M. Fujii, K. Danenberg, P. Danenberg, H-J Lenz, T. Sekikawa, W. Ichikawa
Summary: This biomarker study demonstrated that 62% of patients with RAS-mutant mCRC had no RAS mutations in ctDNA. Patients who had clearance of RAS mutations in ctDNA after triplet-based chemotherapy had better overall survival and post-progression survival.
Article
Oncology
Chiara Nicolazzo, Francesca Belardinilli, Annarita Vestri, Valentina Magri, Gianluigi De Renzi, Michela De Meo, Salvatore Caponnetto, Federica Di Nicolantonio, Enrico Cortesi, Giuseppe Giannini, Paola Gazzaniga
Summary: Liquid biopsies have revealed that the conversion from RAS mutant to RAS wild-type status is a common occurrence in RAS mutant colorectal cancer, indicating a negative selection of RAS mutant clones during the course of the disease. This study aimed to investigate whether the negative selection of RAS mutation in plasma is dependent on drug treatment. The results showed that the use of bevacizumab was significantly associated with the conversion to RAS wild-type status. Patients who converted to RAS wild-type status after bevacizumab treatment had a longer progression-free survival compared to those who remained RAS mutant, suggesting that they could be candidates for second-line treatment with anti-EGFR drugs.
Article
Oncology
Roberto Moretto, Andrew Elliott, Daniele Rossini, Rossana Intini, Veronica Conca, Filippo Pietrantonio, Andrea Sartore-Bianchi, Carlotta Antoniotti, Cosimo Rasola, Mario Scartozzi, Massimiliano Salati, Nicoletta Pella, Maria Alessandra Calegari, Martina Carullo, Francesca Corti, Gianluca Mauri, Matteo Fassan, Gianluca Masi, Pavel Brodskiy, Heinz-Josef Lenz, Anthony Shields, Sara Lonardi, Michael Korn, Chiara Cremolini
Summary: Recent data suggest that BRAFV600E-mutated metastatic colorectal cancer (mCRC) patients with right-sided tumors may benefit from the triplet regimen, while those with left-sided tumors may have a detrimental effect. Differences in tumor biology between right- and left-sided BRAFV600E-mutated CRCs were observed. The use of FOLFOXIRI +/- bevacizumab is supported only in BRAFV600E-mutated mCRC patients with right-sided tumors.
BRITISH JOURNAL OF CANCER
(2022)
Article
Oncology
John H. Strickler, Antonio Cubillo, Jin-Tung Liang, Marc Matrana, Mark Kozloff, Thomas Lowe, Martha Blaney, Mohammad Sahtout, Louie Naumovski, Zev A. Wainberg
Summary: This phase II study compared the safety and efficacy of dilpacimab or bevacizumab in combination with FOLFIRI for previously treated metastatic colorectal cancer (mCRC) patients. The results showed that dilpacimab + FOLFIRI treatment was not well tolerated and did not provide clinical benefit compared to bevacizumab + FOLFIRI in mCRC patients.
Article
Oncology
Carlotta Antoniotti, Alessandra Boccaccino, Robert Seitz, Mirella Giordano, Aurelie Catteau, Daniele Rossini, Filippo Pietrantonio, Lisa Salvatore, Kimberly McGregor, Francesca Bergamo, Veronica Conca, Simone Leonetti, Federica Morano, Giorgio Papiani, Emiliano Tamburini, Maria Bensi, Sabina Murgioni, Douglas Teller Ross, Alessandro Passardi, Isabelle Boquet, Tyler J. Nielsen, Jerome Galon, Matthew Gordon Varga, Brock L. Schweitzer, Chiara Cremolini
Summary: The AtezoTRIBE phase II study shows that adding atezolizumab to first-line FOLFOXIRI plus bevacizumab can prolong progression-free survival in patients with metastatic colorectal cancer (mCRC), especially for those with proficient mismatch repair (pMMR). DetermaIO, a 27-gene expression signature, is able to predict the benefits of immune checkpoint inhibition in triple-negative breast cancer. In this analysis of AtezoTRIBE, the predictive impact of DetermaIO in mCRC was investigated.
CLINICAL CANCER RESEARCH
(2023)
Article
Medicine, General & Internal
Gerald W. Prager, Julien Taieb, Marwan Fakih, Fortunato Ciardiello, Eric Van Cutsem, Elena Elez, Felipe M. Cruz, Lucjan Wyrwicz, Daniil Stroyakovskiy, Zsuzsanna Papai, Pierre-Guillaume Poureau, Gabor Liposits, Chiara Cremolini, Igor Bondarenko, Dominik P. Modest, Karim A. Benhadji, Nadia Amellal, Catherine Leger, Loick Vidot, Josep Tabernero
Summary: In this study, researchers found that treatment with trifluridine-tipiracil plus bevacizumab could prolong overall survival in patients with metastatic colorectal cancer compared to trifluridine-tipiracil alone.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Qin Xu, Junjie Wang, Yang Sun, Yibin Lin, Jing Liu, Yanhong Zhuo, Zhangzhou Huang, Songhua Huang, Ying Chen, Li Chen, Meifang Ke, Li Li, Zirong Li, Junping Pan, Yanwen Song, Rongqiang Liu, Chuanben Chen
Summary: This study investigated the efficacy and safety of sintilimab plus anlotinib as second-line or later therapy for PD-L1-positive advanced cervical cancer patients. The results showed a high objective response rate and disease control rate of sintilimab plus anlotinib in these patients, along with a certain proportion of treatment-related adverse events.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Yukinori Ozaki, Junji Tsurutani, Toru Mukohara, Tsutomu Iwasa, Masato Takahashi, Yuko Tanabe, Hidetaka Kawabata, Norikazu Masuda, Manabu Futamura, Hironobu Minami, Koji Matsumoto, Kenichi Yoshimura, Shigehisa Kitano, Toshimi Takano
Summary: This study investigated the use of nivolumab, bevacizumab, and paclitaxel triple therapy for metastatic breast cancer. The results showed promising efficacy and manageable toxicity of this treatment in the first-line setting.
EUROPEAN JOURNAL OF CANCER
(2022)